Maxim Group Issues Negative Estimate for KindlyMD Earnings

KindlyMD, Inc. (NASDAQ:NAKAFree Report) – Analysts at Maxim Group dropped their Q3 2026 earnings per share estimates for shares of KindlyMD in a research note issued to investors on Wednesday, August 19th. Maxim Group analyst M. Galinko now anticipates that the company will post earnings of ($0.49) per share for the quarter, down from their previous estimate of ($0.43). The consensus estimate for KindlyMD’s current full-year earnings is ($11.31) per share. Maxim Group also issued estimates for KindlyMD’s Q4 2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.76) EPS, Q2 2027 earnings at ($0.74) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.43) EPS and FY2027 earnings at ($2.12) EPS.

Several other analysts also recently commented on NAKA. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a report on Saturday, May 23rd. TD Cowen increased their price target on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a report on Monday, July 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.33.

Read Our Latest Research Report on KindlyMD

KindlyMD Price Performance

NASDAQ:NAKA opened at $6.30 on Friday. The company has a market cap of $112.77 million, a P/E ratio of -0.18 and a beta of 15.95. The firm’s fifty day moving average price is $4.48 and its two-hundred day moving average price is $7.24. KindlyMD has a one year low of $3.33 and a one year high of $432.40.

KindlyMD (NASDAQ:NAKAGet Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The business had revenue of $35.87 million during the quarter.

Institutional Investors Weigh In On KindlyMD

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in shares of KindlyMD in the fourth quarter valued at approximately $151,000. J. Derek Lewis & Associates Inc. bought a new position in KindlyMD during the 4th quarter worth $167,000. Truist Financial Corp acquired a new position in KindlyMD in the 4th quarter valued at $176,000. Waddell & Associates LLC bought a new stake in shares of KindlyMD during the 4th quarter valued at $201,000. Finally, Invesco Ltd. acquired a new stake in shares of KindlyMD during the 4th quarter worth $211,000.

Insider Transactions at KindlyMD

In other KindlyMD news, CEO David F. Bailey bought 4,918 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were purchased at an average price of $5.12 per share, for a total transaction of $25,180.16. Following the transaction, the chief executive officer directly owned 3,180,394 shares in the company, valued at approximately $16,283,617.28. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have bought 196,366 shares of company stock valued at $1,018,088. Insiders own 24.49% of the company’s stock.

KindlyMD Company Profile

(Get Free Report)

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.

Further Reading

Earnings History and Estimates for KindlyMD (NASDAQ:NAKA)

Receive News & Ratings for KindlyMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KindlyMD and related companies with MarketBeat.com's FREE daily email newsletter.